Piper Sandler initiates CareDx stock coverage with overweight rating

Piper Sandler has begun offering coverage on CareDx, Inc. (NASDAQ:CDNA) with an overweight rating and a price target of $100.00. The current trading price of the stock is $80.77, indicating a potential 24% increase from the analyst’s target. This comes after a remarkable 382% gain over the past year. The investment firm believes the market undervalues the company's potential to grow beyond annual transplant volumes by increasing testing frequency among a large, long-lived, and underpenetrated patient base.

The two businesses, Piper Sandler's and CareDx's, together present a path for sustained growth and operating leverage. Analysts predict the company's high gross margin product can grow at mid-teens to 20% by the end of the decade, while CareDx is expected to grow at 30% to 40% annually. The company has an impressive 71% gross profit margin, with revenue growth reaching 39% over the same period.

CareDx estimates a $7 billion opportunity within the solid-organ transplant market, which is part of a broader $12 billion Total Addressable Market. The firm serves over 200 U.S. transplant centers, with testing penetration currently at 25% to 35% in kidney, 35% to 45% in heart, and below 20% in lung transplants. Centers using three or more of CareDx's solutions generate approximately twice the testing volume and revenue compared to other customers.

Despite the significant upside, InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value. For those seeking deeper insights, CareDx is included in the 1,400+ US equities covered by comprehensive Pro Research Reports, providing expert analysis and actionable intelligence. Recently, CareDx reported third-quarter 2026 earnings that surpassed expectations, with adjusted earnings per share of $0.70 against the estimated $0.26.

Revenue for the quarter was $139 million, exceeding the forecasted $121.95 million. The company has raised its full-year outlook as a result. Other analysts, such as BTIG and Canaccord, have maintained a Buy rating on CareDx, with price targets of $92 and $99 respectively, citing the company's strong execution and growth in transplant test volume. This article was generated with AI assistance and reviewed by an editor.